BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 10857572)

  • 1. Monitoring of two intravenous immunoglobulin. Preparations for immunoglobulin G subclasses and specific antibodies to bacterial surface antigens and relation with their levels in treated immunodeficient patients.
    Lamari F; Karamanos NK; Papadopoulou-Alataki E; Kanakoudi-Tsakalidou F; Dimitracopoulos G; Anastassiou ED
    J Pharm Biomed Anal; 2000 Jul; 22(6):1029-36. PubMed ID: 10857572
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An enzyme immunoassay to determine the levels of specific antibodies toward bacterial surface antigens in human immunoglobulin preparations and blood serum.
    Lamari F; Anastassiou ED; Tsegenidis T; Dimitracopoulos G; Karamanos NK
    J Pharm Biomed Anal; 1999 Sep; 20(6):913-20. PubMed ID: 10746960
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determination of slime-producing S. epidermidis specific antibodies in human immunoglobulin preparations and blood sera by an enzyme immunoassay: correlation of antibody titers with opsonic activity and application to preterm neonates.
    Lamari F; Anastassiou ED; Stamokosta E; Photopoulos S; Xanthou M; Dimitracopoulos G; Karamanos NK
    J Pharm Biomed Anal; 2000 Aug; 23(2-3):363-74. PubMed ID: 10933528
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospective evaluation of Streptococcus pneumoniae serum antibodies in patients with primary immunodeficiency on regular intravenous immunoglobulin treatment.
    Simão-Gurge RM; Costa-Carvalho BT; Nobre FA; Gonzalez IG; de Moraes-Pinto MI
    Allergol Immunopathol (Madr); 2017; 45(1):55-62. PubMed ID: 27480789
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Commercial Intravenous Immunoglobulin Preparations Contain Functional Neutralizing Antibodies against the Staphylococcus aureus Leukocidin LukAB (LukGH).
    Wood JB; Jones LS; Soper NR; Nagarsheth M; Creech CB; Thomsen IP
    Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28874371
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunoglobulin subclass concentration in preterm infants treated prophylactically with different intravenous immunoglobins.
    Amato M; Hüppi P; Imbach P; Llauto A; Bürgi W
    Am J Perinatol; 1995 Sep; 12(5):306-9. PubMed ID: 8540928
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody levels to tetanus, diphtheria, measles and varicella in patients with primary immunodeficiency undergoing intravenous immunoglobulin therapy: a prospective study.
    Nobre FA; Gonzalez IG; Simão RM; de Moraes Pinto MI; Costa-Carvalho BT
    BMC Immunol; 2014 Jun; 15():26. PubMed ID: 24952415
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Varicella-specific immunoglobulin G titers in commercial intravenous immunoglobulin preparations.
    Maranich AM; Rajnik M
    Pediatrics; 2009 Sep; 124(3):e484-8. PubMed ID: 19706589
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pneumococcal antibody levels in children with PID receiving immunoglobulin.
    Tuerlinckx D; Florkin B; Ferster A; De Schutter I; Chantrain C; Haerynck F; Philippet P; Strengers P; Laub R
    Pediatrics; 2014 Jan; 133(1):e154-62. PubMed ID: 24366995
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy, tolerability, safety and pharmacokinetics of a nanofiltered intravenous immunoglobulin: studies in patients with immune thrombocytopenic purpura and primary immunodeficiencies.
    Wolf HH; Davies SV; Borte M; Caulier MT; Williams PE; Bernuth HV; Egner W; Sklenar I; Adams C; Späth P; Morell A; Andresen I
    Vox Sang; 2003 Jan; 84(1):45-53. PubMed ID: 12542733
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment potential of pathogen-reactive antibodies sequentially purified from pooled human immunoglobulin.
    Reglinski M; Sriskandan S
    BMC Res Notes; 2019 Apr; 12(1):228. PubMed ID: 30992057
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Streptococcus pneumoniae antibody titres in patients with primary antibody deficiency receiving intravenous immunoglobulin (IVIG) compared to subcutaneous immunoglobulin (SCIG).
    Knutsen AP; Leiva LE; Caruthers C; Rodrigues J; Sorensen RU
    Clin Exp Immunol; 2015 Oct; 182(1):51-6. PubMed ID: 26230522
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro evaluation of the biological activities of IgG in seven Chinese intravenous immunoglobulin preparations.
    Ye S; Li D; Liu F; Lei M; Jiang P; Wang Z; Zhang R; Du X; Cao H; Ma L; Li C
    J Pharm Biomed Anal; 2018 Mar; 151():317-323. PubMed ID: 29413980
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Distribution of IgG subclasses and their biological activity in bioglobulin].
    Bucholc B; Banach W
    Med Dosw Mikrobiol; 1998; 50(1-2):105-13. PubMed ID: 9857620
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunoglobulin G subclass distribution in three human intravenous immunoglobulin preparations.
    Burckhardt JJ; Gardi A; Oxelius VA; Preud'homme JL; Scherz R; Skvaril F; Heiniger HJ
    Vox Sang; 1989; 57(1):10-4. PubMed ID: 2508324
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complement C3 deposition onto bacteria by neonatal serum is not enhanced after the infusion of intravenous immunoglobulin.
    Lassiter HA; Speranza MJ; Hall RT; Meade V; Christensen RD; Parker CJ
    J Perinatol; 1990 Mar; 10(1):27-31. PubMed ID: 2107285
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Different Gm allotype amounts in human intravenous immunoglobulin (IVIG) preparations; survival of foreign Gm allotypes in immunodeficient patients.
    Oxelius VA; Eibl MM
    Clin Exp Immunol; 1996 Nov; 106(2):203-7. PubMed ID: 8918564
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Protective effect and antibody titer of intravenous immunoglobulin (IVIG) against clinical isolates of opportunistic bacteria].
    Nakae T; Nakajima T; Nagai H; Watanabe M; Yokoyama K
    Yakugaku Zasshi; 1994 Dec; 114(12):972-9. PubMed ID: 7869237
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of a novel human intravenous immunoglobulin 10% in patients with primary immunodeficiency diseases: Analysis of a phase III, multicentre, prospective, open-label study.
    Melamed IR; Borte M; Trawnicek L; Kobayashi AL; Kobayashi RH; Knutsen A; Gupta S; Smits W; Pituch-Noworolska A; Strach M; Pulka G; Ochs HD; Moy JN
    Eur J Pharm Sci; 2018 Jun; 118():80-86. PubMed ID: 29522908
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunoglobulin composition of three commercially available intravenous immunoglobulin preparations.
    Herrera AM; Saunders NB; Baker JR
    J Allergy Clin Immunol; 1989 Oct; 84(4 Pt 1):556-61. PubMed ID: 2794297
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.